Home » USA Broker Ratings » Illumina, Inc. – Consenus Indicates Potential -6.4% Downside

Illumina, Inc. – Consenus Indicates Potential -6.4% Downside

Illumina, Inc. with ticker code (ILMN) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 387 and 290 calculating the mean target price we have 347.64. With the stocks previous close at 371.37 this would indicate that there is a downside of -6.4%. There is a 50 day moving average of 333.7 and the 200 moving average now moves to 312.55. The company has a market capitalisation of $55,540m. You can visit the company’s website by visiting: http://www.illumina.com

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn